| Targeting PVR (CD155) and its receptors in anti-tumor therapy JS Kučan Brlić Paola, Lenac Roviš Tihana, Cinamon Guy, Tsukerman Pini ... Cellular and molecular immunology, 2018 | 145* | 2018 |
| Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity A Reches, Y Ophir, N Stein, I Kol, B Isaacson, YC Amikam, A Elnekave, ... Journal for immunotherapy of cancer 8 (1), 2020 | 80 | 2020 |
| Inflammatory monocytes and NK cells play a crucial role in DNAM-1–dependent control of cytomegalovirus infection T Lenac Rovis, P Kucan Brlic, N Kaynan, V Juranic Lisnic, I Brizic, ... Journal of Experimental Medicine 213 (9), 1835-1850, 2016 | 60 | 2016 |
| Cytomegalovirus protein m154 perturbs the adaptor protein-1 compartment mediating broad-spectrum immune evasion I Strazic Geljic, P Kucan Brlic, G Angulo, I Brizic, B Lisnic, T Jenus, ... Elife 9, e50803, 2020 | 11 | 2020 |
| Viral interactions with adaptor-protein complexes: a ubiquitous trait among viral species I Strazic Geljic, P Kucan Brlic, L Musak, D Karner, A Ambriović-Ristov, ... International journal of molecular sciences 22 (10), 5274, 2021 | 9 | 2021 |
| Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern AE Chaouat, I Brizic, PK Brlic, N Atari, L Kliker, O Alfi, M Mandelboim, ... Iscience 25 (9), 2022 | 8 | 2022 |
| Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins M Pribanić Matešić, P Kučan Brlić, T Lenac Roviš, Ž Mačak Šafranko, ... Viruses 14 (2), 443, 2022 | 3 | 2022 |
| Taking on SARS-CoV-2 P Kučan Brlić, I Brizić Elife 11, e80552, 2022 | 2 | 2022 |
| Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity P Tsukerman, A Atieh, A Obeidat, K Paz, G Cinamon, TL Rovis, PK Brlic, ... Cancer Immunology Research 10 (1_Supplement), P075-P075, 2022 | 1 | 2022 |
| 254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity A Atieh, A Obiedat, G Cinamon, TL Rovis, PK Brlic, L Hirsl, O Mandelboim, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A275-A275, 2021 | 1 | 2021 |
| Comprehensive Analysis of Soluble Mediator Profiles in Congenital CMV Infection Using an MCMV Model D Karner, D Kvestak, B Lisnic, M Cokaric Brdovcak, V Juranic Lisnic, ... Viruses 16 (2), 208, 2024 | | 2024 |
| Što je rak? P Kučan Brlić, V Juranić Lisnić, J Železnjak, M Mazor, ... Medicinski fakultet u Rijeci, 2023 | | 2023 |
| Antibodies specific to human nectin-2 O Mandelboim, P Tsukerman, S Jonjic, TL ROVIS, PK BRLIC US Patent App. 17/421,885, 2022 | | 2022 |
| Immunological role of cellular prion protein (PrPC) during cytomegaloviral infection D Karner, D Kveštak, P Kučan Brlić, M Cokarić Brdovčak, B Lisnić, I Brizić, ... Prion 2022, 170-171, 2022 | | 2022 |
| Što rade znanstvenici? J Železnjak, M Mazor, P Kučan Brlić, V Juranić Lisnić, C Paulović, ... | | 2022 |
| Što su protutijela? D Gašparini, P Kučan Brlić, V Juranić Lisnić, J Železnjak, M Mazor, ... | | 2022 |
| NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity P Tsukerman, A Atieh, A Obeidat, K Paz, G Cinamon, TL Rovis, PK Brlic, ... CANCER IMMUNOLOGY RESEARCH 10 (1), 2022 | | 2022 |
| Antibodies specific to human nectin-2 O Mandelboim, P TSUKERMAN, S Jonjic, TL ROVIS, PK BRLIC | | 2020 |
| TIGIT therapy for cancer treatment–TIGITtherapy–ERC O Mandelboim, S Jonjic, P Kucan Brlic, P Tsukerman Impact 2018 (10), 51-53, 2018 | | 2018 |
| ULOGA POLIOVIRUSNOG RECEPTORA U INFEKCIJI CITOMEGALOVIRUSOM P Kučan Brlić University of Rijeka. Faculty of Medicine. Department of Histology and …, 2018 | | 2018 |
